Can-Fite Biopharma Accounts Payable

The latest accounts payable for CANF is $1.2M as of December 2025. That compares with $620K in the prior-year period — up 87.9% year over year. Investors often review this figure alongside Can-Fite Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CANF's accounts payable moved from $620K to $1.2M — a 87.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Can-Fite Biopharma's operating scale or balance-sheet position.

A accounts payable figure of $1.2M for CANF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CANF's accounts payable ($1.2M), review year-over-year change from $620K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Can-Fite Biopharma's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.